Kindly MD (NAKA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 858.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 4.66
• Revenue Growth: -27.67%
• EPS Growth: -110.06%
• Country: US
• Employees: 23
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 376,119,720
• 10 Day Avg. Volume: 1,308,126
• 30 Day Avg. Volume: 858,354
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 1.36
• Enterprise Value/Gross Profit: 1.37
• Enterprise Value/Ebitda: -0.58
• 1Y Price Target: $8.00
• Price Target Upside: 143.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 39 Underperform
• Price Target: $3.00 ▼(-8.54% Downside)

The overall stock score is heavily influenced by the company's poor financial performance and negative valuation metrics. Technical analysis indicates a bearish trend, further weighing down the score. While recent corporate events are positive, they do not offset the significant financial and technical challenges.

Kindly MD Business Overview & Revenue Model

Company Description

Kindly MD (NAKA) is a healthcare company operating in the medical services sector, focusing on providing personalized patient care through innovative health solutions. The company offers a range of services, including telemedicine consultations, chronic disease management, and wellness programs, leveraging technology to enhance patient access and quality of care.

How the Company Makes Money

Kindly MD generates revenue primarily through service fees charged for its telemedicine consultations and chronic disease management programs. These services are often offered on a subscription basis, providing a consistent revenue stream. Additionally, Kindly MD may partner with healthcare providers and insurance companies to expand its service offerings and reach more patients, which can also contribute to its earnings through collaborative agreements and shared revenue models.

Kindly MD Financial Statement Overview

Summary

Kindly MD, Inc. is facing significant financial challenges, with declining revenues and profitability issues. Although the balance sheet shows some stability with a moderate debt level, negative equity in 2023 and reliance on financing raise concerns. Cash flow struggles highlight the need for better operational efficiency and cost management to improve financial health.

Income Statement

Kindly MD, Inc. has faced significant challenges in revenue and profit growth. The Gross Profit Margin remains high at 96.95% for 2024, but the Net Profit Margin is negative at -133.00%, indicating substantial losses. The company has faced revenue decline from the previous year, further exacerbating its profitability issues. The negative EBIT and EBITDA margins highlight operational inefficiencies and the need for cost management.

Balance Sheet

The company's Debt-to-Equity Ratio is 0.31, indicating a moderate level of leverage. However, the negative equity in 2023 raises concerns about financial stability. The Return on Equity is not meaningful due to negative equity in 2023, but the Equity Ratio improved to 69.82% in 2024, reflecting better asset financing through equity.

Cash Flow

Cash flow analysis shows a negative Free Cash Flow of -$3.09 million in 2024, indicating cash management struggles. The Operating Cash Flow to Net Income Ratio is negative, reflecting inefficiencies in converting income into cash. The company heavily relies on financing activities to support its cash needs, which may not be sustainable in the long term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.24M	2.72M	3.77M	3.79M	2.50M
Gross Profit	2.21M	2.64M	-264.17K	-595.29K	914.92K
EBITDA	-5.23M	-3.00M	-1.36M	-2.42M	124.74K
Net Income	-5.47M	-3.62M	-1.62M	-2.54M	149.34K
Balance Sheet
Total Assets	9.89M	3.68M	1.10M	947.00K	447.64K
Cash, Cash Equivalents and Short-Term Investments	6.02M	2.27M	525.50K	186.92K	94.69K
Total Debt	559.02K	783.68K	636.38K	391.13K	109.81K
Total Liabilities	923.39K	1.11M	1.21M	565.98K	174.56K
Stockholders Equity	8.97M	2.57M	-108.41K	381.01K	273.09K
Cash Flow
Free Cash Flow	-5.98M	-3.09M	-463.91K	-457.77K	57.84K
Operating Cash Flow	-5.59M	-3.07M	-449.49K	-140.38K	121.44K
Investing Cash Flow	-3.09M	-401.63K	-14.42K	-317.39K	-63.60K
Financing Cash Flow	8.82M	5.22M	802.49K	550.00K	-45.34K

Kindly MD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAKA, the sentiment is Negative. The current price of 3.28 is below the 20-day moving average (MA) of 9.25, below the 50-day MA of 10.41, and below the 200-day MA of 6.11, indicating a bearish trend. The MACD of -1.77 indicates Positive momentum. The RSI at 30.06 is Neutral, neither overbought nor oversold. The STOCH value of 3.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAKA.

Kindly MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AS	77 Outperform	$21.78B	92.40	4.71%	―	22.86%	―
BTSG	76 Outperform	$4.23B	81.46	1.60%	―	20.60%	―
AUNA	65 Neutral	$468.50M	7.35	15.04%	―	2.83%	―
Sector *	55 Neutral	$6.29B	4.61	-20.95%	6.01%	10.84%	8.15%
CORZ	50 Neutral	$4.16B	―	160.33%	―	-39.43%	90.95%
NAKA	39 Underperform		―	-81.92%	―	-27.67%	-110.06%
BKHA	―		35.22	4.05%	―	―	―

Kindly MD Corporate Events

Kindly MD Enters $5 Billion Sales Agreement

On August 26, 2025, Kindly MD, Inc. entered into a Sales Agreement with several financial agents, including TD Securities and Cantor Fitzgerald, to offer and sell up to $5 billion of its common stock through an at-the-market offering. This strategic move allows Kindly MD to raise capital flexibly, potentially strengthening its financial position and market presence, while providing agents with a commission of up to 2% on the sales.

KindlyMD Completes Merger with Nakamoto Holdings

On August 14, 2025, KindlyMD completed its merger with Nakamoto Holdings, making Nakamoto a wholly-owned subsidiary and establishing a Bitcoin treasury vehicle. The merger, along with PIPE Financing that raised $540 million, aims to advance Bitcoin adoption in global capital markets and enhance KindlyMD’s strategic positioning. The company announced a new leadership team, including David Bailey as CEO, and plans to focus on acquiring Bitcoin at scale, leveraging Nakamoto’s vision for integrating Bitcoin into capital markets. The merger also resulted in changes to the board of directors and executive roles, with new appointments to drive the company’s growth and Bitcoin strategy.

Nakamoto Holdings Appoints New Chief Commercial Officer

On June 25, 2025, Nakamoto Holdings Inc. announced the appointment of Andrew Creighton as Chief Commercial Officer to lead its global Bitcoin growth strategy. Andrew, with extensive experience in scaling international businesses and forming strategic partnerships, will oversee Nakamoto’s commercial strategy, including licensing, partnerships, capital formation, and regional expansion. This move is expected to enhance Nakamoto’s operations and strengthen its position in the Bitcoin industry, potentially impacting its stakeholders by driving Bitcoin’s exposure in new markets.

Kindly MD Approves $51.5M Private Placement for Bitcoin

On June 19, 2025, Kindly MD‘s board approved a private placement of 10.3 million shares at $5.00 each, raising $51.5 million to support Bitcoin purchases and corporate purposes. This financing is part of a merger with Nakamoto Holdings, a Bitcoin-native company, and will close concurrently with the merger. The transaction reflects strong investor demand and aims to bolster Kindly MD’s Bitcoin treasury efforts.

Kindly MD Announces New Chief Investment Officer

On June 18, 2025, Nakamoto Holdings Inc. announced the appointment of Tyler Evans as Chief Investment Officer. Evans, with over a decade of experience in Bitcoin-native financial infrastructure, will lead Nakamoto’s Bitcoin reserve deployment strategy. His role is expected to enhance Nakamoto’s capital strategy and shareholder value, leveraging his expertise and network synergies from his ongoing role at UTXO Management.

Kindly MD CEO to Discuss Crypto Strategies

On June 17, 2025, Nakamoto Holdings Inc. and KindlyMD Inc. announced that David Bailey, CEO of Nakamoto, will participate in a webinar on June 20, 2025, discussing the evolution of crypto balance sheet strategies. This event highlights Nakamoto’s strategic focus on Bitcoin and its efforts to position itself as a leader in the public market for Bitcoin-native companies, potentially impacting its operations and market positioning.